' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.7
USERS' SCORE
Good
Based on 8 Reviews
8.9
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Selenium (elemental)(from 40 mg L-Selenomethionine)
200 mcg
364%
Top Medical Research Studies
9
Selenium compounds may fight breast cancer
Di- and Triselenoesters-Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer.
Direct focus on breast cancer treatment
We set out to explore the effects of selenium-containing compounds on breast cancer cells, particularly focusing on their potential as treatments. Our research involved testing several novel selenoesters on two breast cancer cell lines, MCF-7 and MDA-MB-231, to understand how these compounds can impact cell growth and survival.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
Read More
9
Anticancer effects of selenium compounds
Synthesis of Thiazolidinedione- and Triazole-Linked Organoselenocyanates and Evaluation of Anticancer Activities Against Breast Cancer with Mechanistic Investigations.
Study confirms selenium's potential benefits
We focused on exploring the effectiveness of organoselenocyanates—specifically derivatives of selenium—on triple-negative breast cancer cells. By designing two series of these compounds incorporating unique chemical structures, we aimed to see how they could impact cancer cell growth and behavior.
Through a careful multi-step synthesis process, we successfully created these selenium compounds and put them to the test against cancer cells. After evaluating their anti-proliferative effects, we discovered that one particular compound, known as 15 a, stood out for its promising results. This compound not only hindered cancer cell migration but also triggered significant changes in the cell cycle, causing cells to halt in the G1 phase and promoting early apoptosis, or programmed cell death.
We further investigated how this compound affected the redox balance within the breast cancer cells. Our findings revealed that 15 a demonstrated antioxidant properties by reducing levels of reactive oxygen species (ROS) and increasing the expression of a protective enzyme called TrxR1. On a molecular level, it also activated pathways related to cell signaling that suppressed cancer cell proliferation by manipulating important proteins such as p-ERK, p-Akt, and c-Myc.
These encouraging results highlight the potential of selenium-based treatments as new therapeutic options for battling triple-negative breast cancer. We believe our insights could pave the way for future developments in cancer therapies.
Through a careful multi-step synthesis process, we successfully created these selenium compounds and put them to the test against cancer cells. After evaluating their anti-proliferative effects, we discovered that one particular compound, known as 15 a, stood out for its promising results. This compound not only hindered cancer cell migration but also triggered significant changes in the cell cycle, causing cells to halt in the G1 phase and promoting early apoptosis, or programmed cell death.
We further investigated how this compound affected the redox balance within the breast cancer cells. Our findings revealed that 15 a demonstrated antioxidant properties by reducing levels of reactive oxygen species (ROS) and increasing the expression of a protective enzyme called TrxR1. On a molecular level, it also activated pathways related to cell signaling that suppressed cancer cell proliferation by manipulating important proteins such as p-ERK, p-Akt, and c-Myc.
These encouraging results highlight the potential of selenium-based treatments as new therapeutic options for battling triple-negative breast cancer. We believe our insights could pave the way for future developments in cancer therapies.
Read More
9
Selenium Nanoparticles and Breast Cancer
Biosynthesis of selenium nanoparticles as a potential therapeutic agent in breast cancer: G2/M arrest and apoptosis induction.
Highly relevant to breast cancer
We investigated the effects of selenium nanoparticles (SeNPs) produced by marine yeast on breast cancer cells, specifically the MCF-7 cell line. Through a detailed process of isolating and identifying the potent yeast strains, we found optimal conditions for generating SeNPs, including specific temperature and pH levels. This biosynthesized form of selenium was then characterized using various techniques for its size and shape.
When we examined the impact of these nanoparticles on MCF-7 cells, the results were promising. SeNPs displayed significant anti-cancer properties, yielding lower concentrations needed to inhibit cell growth compared to other cancer types like colon and liver cells. In fact, the concentration required to inhibit the growth of MCF-7 cells was as low as 19.59 µg/ml, while it was higher for other cancer cells. Importantly, there were no adverse effects seen on normal human skin fibroblast (HSF) cells, indicating a level of selectivity that could be beneficial in treatment.
Our findings highlighted that treatment with SeNPs led to a halt in cell cycle progression at the G2/M phase and promoted programmed cell death, or apoptosis, in the MCF-7 cells. We also observed increased oxidative stress levels and a decline in the activity of antioxidant enzymes, which suggests a mechanism through which selenium may exert its effects. In conclusion, the biosynthesized selenium nanoparticles from yeast offer promising insights into potential therapies for breast cancer.
When we examined the impact of these nanoparticles on MCF-7 cells, the results were promising. SeNPs displayed significant anti-cancer properties, yielding lower concentrations needed to inhibit cell growth compared to other cancer types like colon and liver cells. In fact, the concentration required to inhibit the growth of MCF-7 cells was as low as 19.59 µg/ml, while it was higher for other cancer cells. Importantly, there were no adverse effects seen on normal human skin fibroblast (HSF) cells, indicating a level of selectivity that could be beneficial in treatment.
Our findings highlighted that treatment with SeNPs led to a halt in cell cycle progression at the G2/M phase and promoted programmed cell death, or apoptosis, in the MCF-7 cells. We also observed increased oxidative stress levels and a decline in the activity of antioxidant enzymes, which suggests a mechanism through which selenium may exert its effects. In conclusion, the biosynthesized selenium nanoparticles from yeast offer promising insights into potential therapies for breast cancer.
Read More
Most Useful Reviews
9.5
Cancer cell disappearance
During my breast cancer treatment, I started taking one tablet of selenium daily after reading Mitsuishi Iwao's book. I continued with this dosage and a high-protein, vitamin-rich, low-carbohydrate diet throughout pre-operative chemotherapy. Remarkably, the lump shrank significantly, and post-surgery pathology indicated that cancer cells had vanished. Although navigating the chemotherapy's side effects was challenging, I believe the supplements aided my resilience while working. I intend to keep taking it diligently and would recommend it to anyone facing similar challenges during breast cancer treatment.
Read More
9.5
Cancer prevention
Selenium is an essential supplement for cancer prevention. To maintain my health and reduce the risk of tumours, I find this supplement indispensable.
Read More
9.5
Cancer prevention
This yeast-free selenium product is excellent. It significantly contributes to preventing cancer.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.7
9
Anticancer effects of selenium compounds
Synthesis of Thiazolidinedione- and Triazole-Linked Organoselenocyanates and Evaluation of Anticancer Activities Against Breast Cancer with Mechanistic Investigations.
Study confirms selenium's potential benefits
We focused on exploring the effectiveness of organoselenocyanates—specifically derivatives of selenium—on triple-negative breast cancer cells. By designing two series of these compounds incorporating unique chemical structures, we aimed to see how they could impact cancer cell growth and behavior.
Through a careful multi-step synthesis process, we successfully created these selenium compounds and put them to the test against cancer cells. After evaluating their anti-proliferative effects, we discovered that one particular compound, known as 15 a, stood out for its promising results. This compound not only hindered cancer cell migration but also triggered significant changes in the cell cycle, causing cells to halt in the G1 phase and promoting early apoptosis, or programmed cell death.
We further investigated how this compound affected the redox balance within the breast cancer cells. Our findings revealed that 15 a demonstrated antioxidant properties by reducing levels of reactive oxygen species (ROS) and increasing the expression of a protective enzyme called TrxR1. On a molecular level, it also activated pathways related to cell signaling that suppressed cancer cell proliferation by manipulating important proteins such as p-ERK, p-Akt, and c-Myc.
These encouraging results highlight the potential of selenium-based treatments as new therapeutic options for battling triple-negative breast cancer. We believe our insights could pave the way for future developments in cancer therapies.
Through a careful multi-step synthesis process, we successfully created these selenium compounds and put them to the test against cancer cells. After evaluating their anti-proliferative effects, we discovered that one particular compound, known as 15 a, stood out for its promising results. This compound not only hindered cancer cell migration but also triggered significant changes in the cell cycle, causing cells to halt in the G1 phase and promoting early apoptosis, or programmed cell death.
We further investigated how this compound affected the redox balance within the breast cancer cells. Our findings revealed that 15 a demonstrated antioxidant properties by reducing levels of reactive oxygen species (ROS) and increasing the expression of a protective enzyme called TrxR1. On a molecular level, it also activated pathways related to cell signaling that suppressed cancer cell proliferation by manipulating important proteins such as p-ERK, p-Akt, and c-Myc.
These encouraging results highlight the potential of selenium-based treatments as new therapeutic options for battling triple-negative breast cancer. We believe our insights could pave the way for future developments in cancer therapies.
Read More
9
Selenium Nanoparticles and Breast Cancer
Biosynthesis of selenium nanoparticles as a potential therapeutic agent in breast cancer: G2/M arrest and apoptosis induction.
Highly relevant to breast cancer
We investigated the effects of selenium nanoparticles (SeNPs) produced by marine yeast on breast cancer cells, specifically the MCF-7 cell line. Through a detailed process of isolating and identifying the potent yeast strains, we found optimal conditions for generating SeNPs, including specific temperature and pH levels. This biosynthesized form of selenium was then characterized using various techniques for its size and shape.
When we examined the impact of these nanoparticles on MCF-7 cells, the results were promising. SeNPs displayed significant anti-cancer properties, yielding lower concentrations needed to inhibit cell growth compared to other cancer types like colon and liver cells. In fact, the concentration required to inhibit the growth of MCF-7 cells was as low as 19.59 µg/ml, while it was higher for other cancer cells. Importantly, there were no adverse effects seen on normal human skin fibroblast (HSF) cells, indicating a level of selectivity that could be beneficial in treatment.
Our findings highlighted that treatment with SeNPs led to a halt in cell cycle progression at the G2/M phase and promoted programmed cell death, or apoptosis, in the MCF-7 cells. We also observed increased oxidative stress levels and a decline in the activity of antioxidant enzymes, which suggests a mechanism through which selenium may exert its effects. In conclusion, the biosynthesized selenium nanoparticles from yeast offer promising insights into potential therapies for breast cancer.
When we examined the impact of these nanoparticles on MCF-7 cells, the results were promising. SeNPs displayed significant anti-cancer properties, yielding lower concentrations needed to inhibit cell growth compared to other cancer types like colon and liver cells. In fact, the concentration required to inhibit the growth of MCF-7 cells was as low as 19.59 µg/ml, while it was higher for other cancer cells. Importantly, there were no adverse effects seen on normal human skin fibroblast (HSF) cells, indicating a level of selectivity that could be beneficial in treatment.
Our findings highlighted that treatment with SeNPs led to a halt in cell cycle progression at the G2/M phase and promoted programmed cell death, or apoptosis, in the MCF-7 cells. We also observed increased oxidative stress levels and a decline in the activity of antioxidant enzymes, which suggests a mechanism through which selenium may exert its effects. In conclusion, the biosynthesized selenium nanoparticles from yeast offer promising insights into potential therapies for breast cancer.
Read More
9
Selenium compounds may combat resistance
Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells.
Study directly examines selenium's effects
We focused on how selenium compounds could help fight breast cancer, particularly when it comes to overcoming multidrug resistance, a major hurdle in effective treatment. Our research specifically assessed two novel selenoesters, EDAG-1 and EDAG-8, for their potential to inhibit resistance proteins in breast cancer cells.
Through various analyses, we discovered that these compounds, especially EDAG-8, effectively blocked the action of important efflux pumps known as BCRP, MDR1, and MRP1. This action makes cancer cells more susceptible to treatment, giving us a hopeful avenue for developing better therapies. Notably, the testing showed that EDAG-8 outperformed traditional reference compounds, indicating its promising role in treatment strategies.
Our in silico studies further supported these findings, highlighting that EDAG-8's unique structure and lower binding energy to these proteins enhances its anticancer activity. This reveals a compelling potential for selenium-based treatments in the battle against breast cancer, positioning EDAG-8 as an exciting candidate for future drug development.
Through various analyses, we discovered that these compounds, especially EDAG-8, effectively blocked the action of important efflux pumps known as BCRP, MDR1, and MRP1. This action makes cancer cells more susceptible to treatment, giving us a hopeful avenue for developing better therapies. Notably, the testing showed that EDAG-8 outperformed traditional reference compounds, indicating its promising role in treatment strategies.
Our in silico studies further supported these findings, highlighting that EDAG-8's unique structure and lower binding energy to these proteins enhances its anticancer activity. This reveals a compelling potential for selenium-based treatments in the battle against breast cancer, positioning EDAG-8 as an exciting candidate for future drug development.
Read More
9
Selenium nanoparticles boost cancer treatment
Selenium Nanoparticles Synergize with a KRAS Nanovaccine against Breast Cancer.
Limited isolated effect observed
We explored the potential of selenium nanoparticles (SeNPs) in treating breast cancer, especially their effects in combination with a KRAS nanovaccine. Our study utilized various stabilizing agents to develop stable SeNPs, with a focus on bovine serum albumin (BSA). The BSA-stabilized SeNPs were particularly noteworthy, showing remarkable stability under different conditions while remaining effective in targeting cancer cells.
When we tested these nanoparticles, we found that they exhibited enhanced toxicity against cancer cell lines, while not harming normal human cells. This selectivity is promising for cancer treatments. Moreover, we observed significant synergy when we combined BSA-SeNPs with the nanovaccine, leading to substantial reductions in tumor size in a mouse model of breast cancer.
Overall, our findings suggest that selenium nanoparticles, especially when paired with immunotherapy approaches like the nanovaccine, could be a valuable strategy inbreast cancer treatment. This innovative combination offers exciting possibilities for improving cancer immunotherapy outcomes.
When we tested these nanoparticles, we found that they exhibited enhanced toxicity against cancer cell lines, while not harming normal human cells. This selectivity is promising for cancer treatments. Moreover, we observed significant synergy when we combined BSA-SeNPs with the nanovaccine, leading to substantial reductions in tumor size in a mouse model of breast cancer.
Overall, our findings suggest that selenium nanoparticles, especially when paired with immunotherapy approaches like the nanovaccine, could be a valuable strategy inbreast cancer treatment. This innovative combination offers exciting possibilities for improving cancer immunotherapy outcomes.
Read More
9
Selenium compounds may fight breast cancer
Di- and Triselenoesters-Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer.
Direct focus on breast cancer treatment
We set out to explore the effects of selenium-containing compounds on breast cancer cells, particularly focusing on their potential as treatments. Our research involved testing several novel selenoesters on two breast cancer cell lines, MCF-7 and MDA-MB-231, to understand how these compounds can impact cell growth and survival.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.9
9.5
Cancer prevention
Selenium is an essential supplement for cancer prevention. To maintain my health and reduce the risk of tumours, I find this supplement indispensable.
9.5
Cancer prevention
This yeast-free selenium product is excellent. It significantly contributes to preventing cancer.
9.5
Cancer protection
Selenium aids in preventing common cancers, fighting viruses, protecting against cardiovascular disease, and alleviating symptoms of serious illnesses. I highly recommend it!
9.5
Thyroid health
Selenium is vital for thyroid hormones and is one of the top antioxidants. I was lethargic with high blood pressure, and after taking selenium with iodine and L-tyrosine for six months, I felt energised, my weight decreased, and many health issues improved. I take it regularly.
9.5
Cancer cell disappearance
During my breast cancer treatment, I started taking one tablet of selenium daily after reading Mitsuishi Iwao's book. I continued with this dosage and a high-protein, vitamin-rich, low-carbohydrate diet throughout pre-operative chemotherapy. Remarkably, the lump shrank significantly, and post-surgery pathology indicated that cancer cells had vanished. Although navigating the chemotherapy's side effects was challenging, I believe the supplements aided my resilience while working. I intend to keep taking it diligently and would recommend it to anyone facing similar challenges during breast cancer treatment.
Read More
